Tivozanib: Additional Phase II data

Additional data from a placebo-controlled Phase II trial in 272 patients naïve to VEGF therapy showed that once-daily oral tivozanib led to a median PFS of 11.8 months. Median PFS for patients with clear cell RCC who had undergone a prior nephrectomy was 14.8 months. Additionally, PFS was significantly higher in patients with clear cell RCC vs. non-clear cell RCC (12.5 vs. 6.7 months) and in patients with prior nephrectomy vs. no prior nephrectomy (14.1 vs. 8.2 months). All patients received once-daily tivozanib for 16 weeks, after which patients who achieved >=25% tumor regression remained on therapy, patients who experienced <25% tumor change were randomized to receive tivozanib or placebo in a double-blind fashion, and patients with >=25% tumor growth discontinued treatment. Data were presented at the American Society of Clinical Oncology meeting in Chicago. ...